Showing 1 - 20 results of 27 for search 'M. Kolesár', query time: 1.45s Refine Results
  1. 1
    Editorial: Anticancer Potential of Artemisia annua

    Editorial: Anticancer Potential of Artemisia annua by Jill M. Kolesar, Peter H. Seeberger

    Published 2022-02-01
    Get full text
    Article
  2. 2
    Macrophage Repolarization as a Therapeutic Strategy for Osteosarcoma

    Macrophage Repolarization as a Therapeutic Strategy for Osteosarcoma by Namrata Anand, Keng Hee Peh, Jill M. Kolesar

    Published 2023-02-01
    Get full text
    Article
  3. 3
    Association of first primary cancer with risk of subsequent primary cancer among survivors of adult-onset cancers in Kentucky and Appalachian Kentucky

    Association of first primary cancer with risk of subsequent primary cancer among survivors of adult-onset cancers in Kentucky and Appalachian Kentucky by Quan Chen, Quan Chen, Bin Huang, Bin Huang, Abigail M. Anderson, Eric B. Durbin, Eric B. Durbin, Susanne M. Arnold, Susanne M. Arnold, Jill M. Kolesar, Jill M. Kolesar, Jill M. Kolesar

    Published 2023-08-01
    Get full text
    Article
  4. 4
    CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer

    CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer by Justin W. Gorski, Frederick R. Ueland, Jill M. Kolesar

    Published 2020-05-01
    Get full text
    Article
  5. 5
    <i>MUTYH</i> as an Emerging Predictive Biomarker in Ovarian Cancer

    <i>MUTYH</i> as an Emerging Predictive Biomarker in Ovarian Cancer by Megan L. Hutchcraft, Holly H. Gallion, Jill M. Kolesar

    Published 2021-01-01
    Get full text
    Article
  6. 6
    <i>SYNE1</i> Mutation Is Associated with Increased Tumor Mutation Burden and Immune Cell Infiltration in Ovarian Cancer

    <i>SYNE1</i> Mutation Is Associated with Increased Tumor Mutation Burden and Immune Cell Infiltration in Ovarian Cancer by Laura M. Harbin, Nan Lin, Frederick R. Ueland, Jill M. Kolesar

    Published 2023-09-01
    Get full text
    Article
  7. 7
    Artesunate acts through cytochrome c to inhibit growth of pediatric AML cells

    Artesunate acts through cytochrome c to inhibit growth of pediatric AML cells by Kristen S. Hill, Erin E. Schuler, Sally R. Ellingson, Jill M. Kolesar

    Published 2023-12-01
    Get full text
    Article
  8. 8
    Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer—An Opportunity for Targeted Therapy

    Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer—An Opportunity for Targeted Therapy by Laura M. Harbin, Holly H. Gallion, Derek B. Allison, Jill M. Kolesar

    Published 2022-03-01
    Get full text
    Article
  9. 9
    Antineoplastic Drug Synergy of Artesunate with Navitoclax in Models of High-Grade Serous Ovarian Cancer

    Antineoplastic Drug Synergy of Artesunate with Navitoclax in Models of High-Grade Serous Ovarian Cancer by J. Robert McCorkle, Rebecca Ahn, Connie D. Cao, Kristen S. Hill, Charles S. Dietrich, Jill M. Kolesar

    Published 2024-03-01
    Get full text
    Article
  10. 10
    Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant <i>BRCA1</i> Mutant Ovarian Cells

    Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant <i>BRCA1</i> Mutant Ovarian Cells by Brian T. Burgess, Abigail M. Anderson, J. Robert McCorkle, Jianrong Wu, Frederick R. Ueland, Jill M. Kolesar

    Published 2020-02-01
    Get full text
    Article
  11. 11
    EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky.

    EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky. by Kara L Larson, Bin Huang, Quan Chen, Thomas Tucker, Marissa Schuh, Susanne M Arnold, Jill M Kolesar

    Published 2020-01-01
    Get full text
    Article
  12. 12
    KEAP1 Is Required for Artesunate Anticancer Activity in Non-Small-Cell Lung Cancer

    KEAP1 Is Required for Artesunate Anticancer Activity in Non-Small-Cell Lung Cancer by Kristen S. Hill, Anthony McDowell, J. Robert McCorkle, Erin Schuler, Sally R. Ellingson, Rina Plattner, Jill M. Kolesar

    Published 2021-04-01
    Get full text
    Article
  13. 13
    Case report: A unique presentation of a high-grade neuroepithelial tumor with EWSR1::PATZ1 fusion with diagnostic, molecular, and therapeutic insights

    Case report: A unique presentation of a high-grade neuroepithelial tumor with EWSR1::PATZ1 fusion with diagnostic, molecular, and therapeutic insights by Andre Ene, Jing Di, Janna H. Neltner, Thomas Pittman, Susanne M. Arnold, Susanne M. Arnold, Jill M. Kolesar, Jill M. Kolesar, John L. Villano, John L. Villano, John L. Villano, Sara E. Bachert, Sara E. Bachert, Derek B. Allison, Derek B. Allison

    Published 2023-01-01
    Get full text
    Article
  14. 14
    Preclinical Evaluation of Artesunate as an Antineoplastic Agent in Ovarian Cancer Treatment

    Preclinical Evaluation of Artesunate as an Antineoplastic Agent in Ovarian Cancer Treatment by Anthony McDowell, Kristen S. Hill, Joseph Robert McCorkle, Justin Gorski, Yilin Zhang, Ameen A. Salahudeen, Fred Ueland, Jill M. Kolesar

    Published 2021-02-01
    Get full text
    Article
  15. 15
    Implementation of Nurse Navigation Improves Rate of Molecular Tumor Testing for Ovarian Cancer in a Gynecologic Oncology Practice

    Implementation of Nurse Navigation Improves Rate of Molecular Tumor Testing for Ovarian Cancer in a Gynecologic Oncology Practice by Taylor A. Rives, Heather Pavlik, Ning Li, Lien Qasrawi, Donglin Yan, Justine Pickarski, Charles S. Dietrich, Rachel W. Miller, Frederick R. Ueland, Jill M. Kolesar

    Published 2023-06-01
    Get full text
    Article
  16. 16
    DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden.

    DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden. by McKayla J Riggs, Nan Lin, Chi Wang, Dava W Piecoro, Rachel W Miller, Oliver A Hampton, Mahadev Rao, Frederick R Ueland, Jill M Kolesar

    Published 2020-01-01
    Get full text
    Article
  17. 17
    Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.

    Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer. by J Robert McCorkle, Justin W Gorski, Jinpeng Liu, McKayla B Riggs, Anthony B McDowell, Nan Lin, Chi Wang, Frederick R Ueland, Jill M Kolesar

    Published 2021-01-01
    Get full text
    Article
  18. 18
    Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer

    Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer by J. Robert McCorkle, Justin W. Gorski, Jinpeng Liu, McKayla B. Riggs, Anthony B. McDowell, Nan Lin, Chi Wang, Frederick R. Ueland, Jill M. Kolesar

    Published 2021-01-01
    Get full text
    Article
  19. 19
    Utilizing Patient-Derived Epithelial Ovarian Cancer Tumor Organoids to Predict Carboplatin Resistance

    Utilizing Patient-Derived Epithelial Ovarian Cancer Tumor Organoids to Predict Carboplatin Resistance by Justin W. Gorski, Zhuwei Zhang, J. Robert McCorkle, Jodi M. DeJohn, Chi Wang, Rachel W. Miller, Holly H. Gallion, Charles S. Dietrich, Frederick R. Ueland, Jill M. Kolesar

    Published 2021-08-01
    Get full text
    Article
  20. 20
    Real-World Evaluation of Universal Germline Screening for Cancer Treatment-Relevant Pharmacogenes

    Real-World Evaluation of Universal Germline Screening for Cancer Treatment-Relevant Pharmacogenes by Megan L. Hutchcraft, Nan Lin, Shulin Zhang, Catherine Sears, Kyle Zacholski, Elizabeth A. Belcher, Eric B. Durbin, John L. Villano, Michael J. Cavnar, Susanne M. Arnold, Frederick R. Ueland, Jill M. Kolesar

    Published 2021-09-01
    Get full text
    Article

Search Tools: